Cargando…
Combination L-Glutamine with Gemcitabine and Nab-Paclitaxel in Treatment-Naïve Advanced Pancreatic Cancer: The Phase I GlutaPanc Study Protocol
Advanced pancreatic cancer is underscored by progressive therapeutic resistance and a dismal 5-year survival rate of 3%. Preclinical data demonstrated glutamine supplementation, not deprivation, elicited antitumor effects against pancreatic ductal adenocarcinoma (PDAC) alone and in combination with...
Autores principales: | Gong, Jun, Osipov, Arsen, Lorber, Jeremy, Tighiouart, Mourad, Kwan, Albert K., Muranaka, Hayato, Akinsola, Rasaq, Billet, Sandrine, Levi, Abrahm, Abbas, Anser, Davelaar, John, Bhowmick, Neil, Hendifar, Andrew E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216251/ https://www.ncbi.nlm.nih.gov/pubmed/37239063 http://dx.doi.org/10.3390/biomedicines11051392 |
Ejemplares similares
-
Gut microbiome and pancreatic cancer cachexia: An evolving relationship
por: Hendifar, Andrew, et al.
Publicado: (2022) -
Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer
por: Thiruvalluvan, Manish, et al.
Publicado: (2022) -
Plasma Metabolomics Predicts Chemotherapy Response in Advanced Pancreatic Cancer
por: Muranaka, Hayato, et al.
Publicado: (2023) -
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022) -
Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma
por: Gong, Jun, et al.
Publicado: (2022)